Department of Obstetrics and Gynecology, University of Calgary, 4th Floor North Tower - Foothills Medical Centre, 1403 29 St NW, Calgary, AB, T2N 2T9, Canada.
BMC Pregnancy Childbirth. 2018 Jan 23;18(1):40. doi: 10.1186/s12884-018-1662-z.
Cell-free DNA (cfDNA) screening has recently acquired tremendous attention, promising patients and healthcare providers a more accurate prenatal screen for aneuploidy than other current screening modalities. It is unclear how much knowledge regarding cfDNA screening obstetrical providers possess which has important implications for the quality and content of the informed consent patients receive.
A survey was designed to assess obstetrical provider knowledge and attitudes towards cfDNA screening and distributed online through the Society of Obstetricians & Gynecologists of Canada (SOGC). Chi-squared tests were used to detect differences in knowledge and attitudes between groups.
207 respondents completed the survey, composed of 60.6% Obstetricians/Gynecologists (OB/GYN), 15.4% Maternal Fetal Medicine (MFM) specialists, 16.5% General Practitioners (GP), and 7.5% Midwives (MW). MFM demonstrated a significant trend of being most knowledgeable about cfDNA screening followed by OB/GYN, GP, and lastly MW in almost all aspects of cfDNA screening. All groups demonstrated an overall positive attitude towards cfDNA screening; however, OB/GYN and MFM demonstrated a significantly more positive attitude than GP and MW. Despite not yet being a diagnostic test, 19.4% of GP would offer termination of pregnancy immediately following a positive cfDNA screen result compared to none of the MFM and only few OB/GYN or MW.
We have demonstrated that different types of obstetrical providers possess varying amounts of knowledge regarding cfDNA screening with MFM currently having greater knowledge to all other groups. All obstetrical providers must have adequate prenatal screening understanding so that we can embrace the benefits of this novel and promising technology while protecting the integrity of the informed consent process.
无细胞 DNA(cfDNA)筛查最近引起了极大的关注,为患者和医疗保健提供者提供了比其他当前筛查方法更准确的非整倍体产前筛查。目前尚不清楚产科医生对 cfDNA 筛查的了解程度,这对患者获得的知情同意的质量和内容有重要影响。
设计了一项调查,以评估产科医生对 cfDNA 筛查的知识和态度,并通过加拿大妇产科医生学会(SOGC)在线分发。使用卡方检验检测组间知识和态度的差异。
207 名受访者完成了调查,其中包括 60.6%的妇产科医生(OB/GYN)、15.4%的母胎医学专家(MFM)、16.5%的全科医生(GP)和 7.5%的助产士(MW)。MFM 在 cfDNA 筛查的几乎所有方面都表现出最了解 cfDNA 筛查的明显趋势,其次是 OB/GYN、GP,最后是 MW。所有组对 cfDNA 筛查均表现出总体积极的态度;然而,OB/GYN 和 MFM 比 GP 和 MW 表现出更积极的态度。尽管 cfDNA 筛查尚未成为诊断性测试,但 19.4%的 GP 在 cfDNA 筛查结果呈阳性后会立即提供终止妊娠,而 MFM 没有,只有少数 OB/GYN 或 MW 会提供。
我们已经证明,不同类型的产科医生对 cfDNA 筛查的了解程度不同,目前 MFM 对所有其他组的了解程度更高。所有产科医生都必须对产前筛查有足够的了解,以便我们能够利用这项新颖且有前途的技术的优势,同时保护知情同意过程的完整性。